Study title: "Open label, phase III, dose titration, multicenter study to assess the efficacy and safety of fluvastatin sodium capsules and fluvastatin sodium extended-release tablets (20, 40 and 80 mg) given orally at bedtime for 114 weeks in pediatric patiens with heterozygous familial hypercholesterolemia"
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Cardiovascular Diseases | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report, Please see report, Please see report, Please see report, Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: FLUVASTATIN | |||||
| ATC code: C10AA04 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: CXUO320B 2301 | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |